Fideuram Asset Management Ireland dac Invests $10.12 Million in Regeneron Pharmaceuticals, Inc. $REGN

Fideuram Asset Management Ireland dac bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 13,111 shares of the biopharmaceutical company’s stock, valued at approximately $10,120,000. Regeneron Pharmaceuticals accounts for 0.7% of Fideuram Asset Management Ireland dac’s holdings, making the stock its 29th biggest holding.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. National Pension Service lifted its position in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after purchasing an additional 82,853 shares during the period. Basepoint Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $40,000. Rothschild Investment LLC lifted its position in shares of Regeneron Pharmaceuticals by 60.1% in the 4th quarter. Rothschild Investment LLC now owns 975 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 366 shares during the period. SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $1,171,000. Finally, Moors & Cabot Inc. lifted its position in shares of Regeneron Pharmaceuticals by 10.1% in the 4th quarter. Moors & Cabot Inc. now owns 785 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 72 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research note on Monday, May 18th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Stock Down 1.0%

Shares of Regeneron Pharmaceuticals stock opened at $621.52 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a 50-day moving average of $721.74 and a 200 day moving average of $745.26. The firm has a market cap of $65.71 billion, a price-to-earnings ratio of 15.14, a PEG ratio of 1.39 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the business earned $8.22 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.